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Abstract
Background: The aim of this study was to investigate the effect of downregulating Hedgehog pathway by
GANT61 on human glioma cells, examine the consequent changes of temozolomide (TMZ)-induced effects and
explore the molecular mechanisms.
Methods: The cytotoxicity of a Gli1/2 inhibitor, GANT61 was examined both alone and in combination with TMZ in
human glioma cell lines. The mRNA and protein expression alterations were determined by quantitative real-time
polymerase chain reaction (qRT-PCR) and Western blot, respectively. CCK-8 assay detected the cell proliferative
capability. Apoptotic cell number was measured by flow cytometry. The transwell assay was used to test the cell
invasive capability. DNA damage effect was identified by COMET assay and γH2AX expression.
Results: Proliferation of tumor cells treated with GANT61 in combination with TMZ was significantly suppressed
compared with those treated with either drug used alone. The combination treatment induced a higher rate of
apoptosis, DNA damage and reduced the invasive capability of glioma cells. DNA damage repair enzyme MGMT
and the Notch1 pathway increased in the cells treated by TMZ treatment. However, GANT61 could abrogated the
protein increasing.
Conclusions: GANT61 sensitizes glioma cells to TMZ treatment by enhancing DNA damage effect, decreasing
MGMT expression and the Notch1 pathway.
Keywords: Glioma, GANT61, Temozolomide, Hedgehog, DNA damage, O6-methylguanine DNA methyltransferase
(MGMT), Notch1 pathway
Background
Glioma is the most common primary malignant brain
tumor in adults [1, 2]. Despite the development of ag-
gressive comprehensive treatments, the median overall
survival (OS) of patients with glioblastoma (GBM), the
most malignant type of glioma, has only marginally
changed over the past 25 years and still remains about
12 to 15 months [3–6]. Thus, novel therapeutic ap-
proaches to cure this malignancy are urgently needed.
Temozolomide (TMZ) is an oral chemotherapeutic
drug for GBM which penetrates into the brain and dam-
ages DNA by the induction of DNA O6-methylguanine
[4, 7–10]. However, the DNA repair enzyme O6-methyl-
guanine methyltransferase (MGMT) could abrogate the
cytotoxic O6-methylguanine DNA adduct before it
causes harm, which may be the important mechanism of
TMZ resistance [11, 12]. Indeed, lower response to
TMZ treatment has been observed in patients with high
MGMT and inactivation of the MGMT gene is associ-
ated with longer patient survival [13, 14].
In addition, the Hedgehog (Hh) pathway involving in
development and cancer, is indispensable for epithelial-to-
mesenchymal transition (EMT), metastasis and invasion,
cancer stemness, and chemoresistance [15–17]. Moreover,
the inhibition of the activity of GLI, the functional tran-
scription activators of the Hh pathway, can interfere with
almost all DNA repair types in human cancer, which indi-
cates an important role of Hh/Gli in tumor cells’ survival
from DNA damage induced by chemotherapy or
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radiotherapy [18]. Sonic hedgehog could promote tumor
proliferation in a Notch-dependent manner [19–22]. The
Hh and Notch pathways interact to control the EMT/
MET [19]. Hes-1, a primary target gene of Notch1, can be
activated by both Notch and Hh signaling [23–25].
Thus, Hh signaling may serve as an important thera-
peutic target to overcome DNA repair induced by TMZ
treatment and consequently, to increase the chemother-
apeutic response in the treatment of cancer. In the
present study, we investigated the effect of Gli1/2 down-
regulation by GANT61 on TMZ induced cytotoxicity in
U87 and U251 glioma cells. By comparing the effects of
GANT61, TMZ treatment, and their combination in gli-
oma cell proliferation, invasion/EMT, and apoptosis, we
found a synergistic action between GANT61 and TMZ
treatment. Our results revealed the important role of
GLI inhibitor GANT61 in enhancing the sensitivity of
glioma cell for TMZ.
Methods
Datasets used in this study
Gene expression profiling datasets were obtained from
the Chinese Glioma Genome Atlas (CGGA) [26] (http://
www.cgga.org.cn), including the mRNA array of 305
samples and RNA sequencing of 105 samples.
Tumor cell line
Human GBM cell lines U251 and U87 were purchased
from the Chinese Academy of Sciences Cell Bank. A hu-
man oligodendroglia cell line (OL) was a kind gift from
Prof. Fengmin Zhang of Harbin Medical University. The
cells were maintained in a 37 °C, 5% CO2 incubator in
Dulbecco’s Modified Eagle’s Medium (DMEM, Corning,
USA) supplemented with 10% fetal bovine serum (FBS,
Biological Industries, Israel). We assembled the Cancer
Cell Line Encyclopedia (CCLE) (www.broadinstitute.org/
ccle) and screened 208 differential expressive genes
(Additional file 1A, Fold changes ≥ 2), including GFAP,
S100B, IGFBP2 (Additional file 1B) and so on.
Reagents
TMZ (Sigma-Aldrich, USA) and GANT61 (Selleck
Chemical, USA) were dissolved in 10% dimethylsulfoxide
(DMSO, Sigma) to create a stock solution (TMZ:
100 mg/ml; GANT61: 10 mM). DMSO concentration
was kept below 0.1% in all the cell cultures and did not
exert any detectable effect on cell growth or cell death.
Recombinant Human Shh (rShh, 1 μg/mL) was pur-
chased from R&D, Minnesota, USA. Primary antibodies
used for Western Blot analysis were rabbit anti-Gli1
(CST, USA), Gli2 (Proteintech, USA), N-cadherin (CST),
Vimentin (Abcam, England), Fibronectin (Abcam),
Notch1 (Abcam), Hes1 (Abcam), MGMT (Proteintech),
γH2AX (CST), GAPDH (Wanleibio, China) and mouse
anti-E-cadherin (CST); horseradish peroxidase–conju-
gated secondary antibody (goat anti-rabbit or anti-
mouse) were purchased from ZSGB-BIO.
Cell viability assay
The cytotoxicity of TMZ and GANT61 on U87 and
U251 cells was determined by Cell Counting Kit-8
(CCK-8, Dojindo, Japan) assay. Tumor cells were seeded
at 2-5 × 103 cells/well (0.1 ml) in 96-well flat bottom
plates and incubated overnight at 37 °C. After exposure
to the above described treatment for 24, 48, and 72 h,
CCK-8 (10 μl, 10%) was added to each well once every
hour before incubation ended. Then its absorbance at
450 nm was measured by a microplate reader (IMARK).
All experiments were repeated in triplicate.
Apoptosis detection
U251 and U87 cells were plated in 6-well plates and
treated with TMZ or GANT61 or a combination of the
two. The apoptosis ratio was analyzed 48 h post-
treatment via using Annexin V-FITC Apoptosis Detec-
tion Kit (BD Biosciences, San Diego, CA) according to
the manufacturer’s instructions. Annexin V-FITC and
propidium iodide (PI) double staining was used to evalu-
ate the percentages of apoptosis. Annexin V− and PI−
cells were used as controls. Annexin V+ and PI− cells
were designated as apoptotic, and Annexin V+ and PI+
cells as necrotic. Tests were repeated in triplicate.
In vitro invasion assays
Transwell membranes coated with Matrigel (BD Biosci-
ences, San Jose, CA) were used to assay the invasive
ability of glioma cells in vitro. Treated cells were plated
at 5 × 104 per well in the upper chamber in serum-free
medium. FBS 10% was added to the medium in the
lower chamber. After incubation for 24 h, non-invading
cells were removed from the top well with a cotton
swab, while the bottom cells were fixed with 95% etha-
nol, stained with 0.1% crystal violet, and photographed
in three independent 10× fields for each well. Three
independent experiments were conducted and used to
calculate fold migration relative to the blank control
while the error was calculated as the standard error (SE).
Western blot
Cell lysates were harvested, equivalent amounts of total
protein were separated by 10% SDS polyacrylamide gel
electrophoresis (SDS-PAGE), and transferred to polyvinyli-
dene difluoride (PVDF) membranes. After blocking with
5% fat-free milk and 0.1% Tween-20 in tri-buffered saline
with Tween (TBST) for 1.5 h at room temperature, mem-
branes were incubated with diluted anti-Gli1, Gli2, E-
cadherin, N-cadherin, Vimentin, Fibronectin, MGMT,
Notch1, Hes1, γH2AX (Ser139) and anti-GAPDH primary
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antibodies. Horseradish peroxidase-conjugated anti-mouse
or anti-rabbit secondary antibodies were used, and bound
antibodies were detected using the ECL system.
Quantitative RT-PCR (qRT-PCR) analysis
Total RNA was extracted using Trizol Reagent (Invitro-
gen, USA) according to the manufacturer’s instructions.
Total cDNA was reversely transcribed from 1 μg of total
RNA (Perfect Real Time, Takara, Japan). To quantify gene
expression, two-step qRT-PCR was performed using a
FastStart Universal SYBR Green Master (ROX) by Roche
LightCyclerR Real Time System. Expression levels were
normalized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). The PCR conditions were hot-start at 95 °C
(15 s), with annealing and extension at 60 °C (60 s) for
40 cycles, followed by a melting curve analysis. All qRT-
PCR data were analyzed using the 2-ΔΔCt method. And the
primers used are shown in Additional file 2.
COMET assay
The comet assay (Trevigen, Gaithersburg, MD) was per-
formed according to the manufacturer’s protocol using
alkaline conditions. Cell samples were handled under
dimmed light to prevent DNA damage from ultraviolet
light. Combine cells at 1 × 105/ml with molten LMAgar-
ose and immediately pipette 50 μl onto CometSlide.
After placing slides flat at 4 °C for 10 min, immerse
slides in lysis solution for 60 min and freshly prepared
Alkaline Unwinding Solution, pH > 13 for 20 min. Elec-
trophoresis was carried out at the rate of 1.0 V/cm for
30 min. The slides were removed from the electrophor-
esis chamber, washed in deionized water for 5 min and
in ice cold 70% ethanol for 5 min. Subsequently, the
slides were air-dried, and DNA was stained with 50 μl of
SYBR Green I dye (Sangon Biotech, 1:10,000 in Tris-
EDTA buffer, pH 7.5) for 30 min and immediately ana-
lyzed using a fluorescence microscope (Axiovert 200,
Carl Zeiss). Data was analyzed using CometScore
(TriTek, Sumerduck, VA).
Statistical analysis
Gene set variation analysis (GSVA) with Gli expression
was analyzed by GSVA package [27] of R (https://
www.r-project.org/). Data are presented as mean ± SD.
All statistical analyses were performed using SPSS ver-
sion 13.0 software (Chicago, IL, USA). The Student’s t-
test was used to analyze the difference between the
means of treatment and control groups. One-way ana-
lysis of variance (ANOVA) was used to analyze the sig-
nificance among three or more groups, and the Fisher’s
least significant difference (LSD) method was used for
multiple comparisons when the probability for ANOVA
was statistically significant. Data were considered statis-
tically significant at P <0.05 level.
Results
Gli1 is a prognostic marker in glioma and participates in
variety of biological behaviors
As shown in Fig. 1a, patients with glioblastoma contain-
ing high or low expression of Gli1 showed a consider-
ably different prognosis in the CGGA mRNA array
dataset and RNA sequencing dataset. Patients with low
expression of Gli1 had a favorable prognosis in CGCG
(P = 0.0177 and P = 0.0301, respectively). Cox regression
analysis also revealed that GLI expression was associated
with the overall survival of patients with glioblastoma
from the CGGA mRNA and RNA sequencing datasets
(P = 0.019, HR = 1.588, 95% CI = 1.080–2.334; P = 0.032,
HR = 1.687, 95% CI = 1.045–2.725, respectively).
Gene set variation analysis (GSVA) illustrated that GLI
was associated with several biological behaviors besides
the Hh pathway, including positive regulation of the
DNA metabolic process and DNA damage response
signal transduction, and negative regulation of DNA
binding and protein-DNA complex assembly (Fig. 1b).
Up- and downregulated genes associated with indicated
biological behaviors went positively and negatively re-
lated to GLI expression. These function analyses were
related to DNA metabolism, replication, DNA damage
repair and glioma malignant progression. Therefore, we
thought to find out the role of Hh inhibitor GANT61 in
glioma cells’ survival.
Reduction in the survival of human glioma cells after
treatment with GANT61
In our present study, we confirmed that GANT61 (Fig. 2a)
could inhibit the Gli1/2 expression (Fig. 2b and c. *P < 0.05,
**P < 0.01). To clarify the action of GANT61 as a single an-
titumor agent, we first performed a CCK-8 assay using U87
and U251 glioma cells treated with GANT61 at concentra-
tions of 1.25 to 20 μM for 24, 48, and 72 h, respectively. As
shown in Fig. 2d, GANT61 exerted an inhibitory effect on
glioma cells in a dose and time dependent manner (*, &, #
P < 0.05; **, && and ## P < 0.01; ***, &&& and ### P <
0.001 compared to Control). The concentration of inhibited
cell viability (IC50) was 10.24 μM for 24 h, 4.38 μM for
48 h, and 4.39 μM for 72 h in U87 cells, while it was
7.38 μM for 48 h, and 7.59 μM for 72 h in U251 cells. How-
ever, treatment with GANT61 at the same concentration
for the same amount of time did not induce significant
cytotoxicity of human OL cells, except for those treated at
20 μM (Additional file 3). The transwell assay revealed that
the numbers of invasive cells at different concentrations of
GANT61 were significantly reduced compared with the
control group (Fig. 2e and f. * P < 0.05, **P < 0.01, ***P <
0.001). Next, we observed that the population of apoptotic
cells was larger among the glioma cells treated with
GANT61 than the untreated cells (Fig. 2g and h. *P < 0.05,
**P < 0.01).
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GANT61 enhances the suppression of TMZ for the glioma
cells’ biological behavior
To detect the cytotoxicity of combining TMZ and
GANT61, we first used a CCK-8 assay to determine the
sensitivity of U251 to the TMZ. The result showed that
the medial IC50 was 124 μM and 99 μM at 48 h and 72 h,
respectively (Additional file 4). We referred to previous re-
ports [28, 29] for the TMZ sensitivity of U87. As shown in
Fig. 3b, the combined effect of TMZ and GANT61 exhib-
ited the highest of proliferation inhibition effect (*P < 0.05,
**P < 0.01 vs. control at 24 h and 48 h). This GANT61–in-
duced potentiation of the effects of TMZ was recognized
at a lower concentration than that needed to induce cyto-
toxicity with TMZ alone. Isobologram analyses indicated
that the effects of the combinations of GANT61 and
TMZ in both U87 and U251 were both synergistic.
Then, a transwell assay was performed to demonstrate
that TMZ plus GANT61 suppressed the invasive cap-
ability of glioma cells. As shown in Figs. 2e, f and 4, the
invaded cell numbers in the GANT61 group were
smaller than those in the Control group, showing a
negative effect of GANT61 on the invasion ability of
U251 and U87 cells (P < 0.05). Compared to the TMZ
treatment, the combination of GANT61 and TMZ treat-
ment caused a more significant reduction of the invasion
rate (Fig. 4. *P < 0.05, **P < 0.01).
Next, after 2 days of treatment with the combination
of TMZ and GANT61, a significant increase in the num-
ber of apoptotic cells was noted when compared to
TMZ or GANT61 used alone at the same dose (Fig. 5.
*P < 0.05, **P < 0.01). The result indicated that GANT61
enhances TMZ-induced apoptosis.
Treatment with the combination of TMZ and GANT61
reverses epithelial-to-mesenchymal transition (EMT) of
glioma cells
QRT-PCR analysis revealed a significant increase of epi-
thelial cadherin (E-cadherin) mRNA expression and a
Fig. 1 Gli1 is a prognostic marker in glioma and participates in variety of biological behaviors. a A Kaplan-Meier test estimates the survival for glioma
patients. Patients with low expression of Gli1 had a favorable prognosis in the CGCG-array and CGGA-seq (P= 0.0177 and P= 0.0301, respectively). b GSVA
with GLI expression. Gene expression signatures of glioma-associated biological behaviors, including the “Hh signaling pathway”, “DNA metabolic process
(positive regulation)”, “DNA binding (negative regulation)”, “DNA replication”, “DNA modification”, “protein-DNA complex assembly”, “DNA catabolic
process” and “DNA damage response signal transduction by the p53 class mediator” were generated from the Molecular Signature Database. The GLI
expression went higher from left to right. A high enrichment score indicates positive correlation with GLI expression and a low enrichment score
indicates the reverse
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significant decrease of mesenchymal markers N-
cadherin, Vimentin, and Fibronectin expression in
GANT61 treated glioma cells (Fig. 6a and b). Interest-
ingly, glioma cells also exhibited lower transcript levels
of N-cadherin, Vimentin and Fibronectin, and upregu-
lated E-cadherin transcript after incubation with 100 μM
TMZ for 48 h. Compared with TMZ treatment alone,
combined TMZ and GANT61 induced a further reduc-
tion of N-cadherin, Vimentin, and Fibronectin expres-
sion and augmented the elevation of E-cadherin
transcript (Fig. 6a and b). Further, we tested whether
these treatments could modulate the expression of pro-
teins that regulate EMT. Results of Western blot were
manifested according to the protein level alterations.
Fig. 2 GANT61 inhibited the survival of human glioma cells in vitro. a Chemical structure and molecular weight of GANT61. b U87 and U251 glioma cells
were treated with GANT61 (5 μM) for 48 h. Gli1 and Gli2 expression were determined by Western blot and (c) qRT-PCR analysis. GAPDH was used as the
loading control. d U87 and U251 cells were cultured in 96-well plates, respectively. Relative proliferation of glioma cells treated with different doses of
GANT61 for different durations were determined by CCK-8. GANT61 treatment significantly decreased cells proliferation in a dose- and time-dependent
manner. e, f GANT61 inhibited invasion. Transwell assay showed that the invasive capability of U87 or U251 cells treated with GANT61 (5 μM) was weaker
than the control in a dose-dependent manner. g, h GANT61 induced apoptosis. U87 and U251 cells were either solvent-treated (Control) or challenged
with GANT61 for 36 h, and then, cell apoptosis was examined by flow cytometry assay using the Annexin V/PI. Annexin V analysis showed that glioma cells
treated with GANT61 displayed greater apoptosis than the control group. Data are from one of three representative experiments. The error bars represent
standard error. Data are shown as mean ± SEM for the three replicates. Statistical significance levels are indicated as *P< 0.05, **P< 0.01, ***P< 0.001
compared with control group
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Similar conclusions could be drawn based on Western
blot analysis. (Fig. 6c and d).
GANT61 enhances DNA damage effect initiated by TMZ
treatment
To elucidate the mechanisms by which the combination
of TMZ and GANT61 lead to more tumor cells growth
retardation or apoptosis, glioma cells were treated with
GANT61 (5 μM), TMZ (100 μM) or both of them for
48 h. Gli1 and Gli2, which are associated with TMZ re-
sistance and TMZ-activated DNA damage repair, were
obviously down-regulated compared with the single
therapy groups (Fig. 7a).
Phosphorylated histone H2AX (γH2AX) is used as a
biomarker of cellular response to DNA double-strand
breaks (DSBs), and its potential for monitoring DNA
damage and repair in human populations has been ex-
plored in many studies [30, 31]. Herein, the expression
of γH2AX was examined following exposure to
GANT61 and (or) TMZ for up to 40 h. TMZ treatment
alone triggered phosphorylation of H2AX slightly,
whereas a much higher level of γH2AX was observed
after GANT61 was added (Fig. 7b), suggesting substan-
tially more unresolved DNA DSBs in the combination
treatment versus single-treated cells.
In addition, single cells were analyzed by the COMET
assay, which detects DNA damage by altering the pat-
tern of cellular elution through agarose gels. Compared
to groups treated with TMZ or GANT61 alone, signifi-
cant changes in elution profiles were detected in the
combination of TMZ and GANT61-treated cells by
fluorescence microscopy, Tail Moment and Tail Length
(Fig. 7c and d). This indicated a role of DNA damage
signaling in combination of TMZ and GANT61-induced
cytotoxicity. Collectively, data demonstrated that the
combination of Hh-inhibitor and TMZ result in more
evidently reduced cell growth, increased cell death and
induction of DNA damage that is associated with
Fig. 3 GANT61 enhanced the proliferation-inhibiting effect of TMZ. a Cells were cultured in 96-well plates and then treated with solvent only
(Control) or increasing doses of TMZ with 5 μM GANT61 for 48 h. Relative proliferation of U87 and U251 cells treated with GANT61 and different
doses of TMZ were determined by CCK-8. b Cells were seeded into 96-well plates and then treated with Control, GANT61 (1 μM), TMZ (60 μM)
and GANT61 + TMZ for 24 and 48 h. Cell viability was examined using the CCK-8 assay. GANT61 + TMZ treatment resulted in a significant decrease
in cell proliferation. Data are mean ± SEM for the three replicates. *P < 0.05, **P < 0.01
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reduced Gli1 and Gli2 protein levels. These findings
emphasize the significance of the Hh signaling pathway
in human glioma cell growth and survival, regulated at
the level of the GLI genes.
GANT61 abrogates the MGMT, Notch1, and Hes1
overexpression induced by TMZ treatment
Glioma cells treated with TMZ exhibited significant in-
creases in MGMT, Notch1 and Hes1 mRNA, and pro-
tein levels (Fig. 8a and b). However, these upregulations
were suppressed by GANT61, as shown in Fig. 8. Also,
MGMT, Notch1 and Hes1 expression levels in the
GANT61 group were obviously lower than those in the
control group (P < 0.05, **P < 0.01). To further demon-
strate the importance of the Hh pathway in the regula-
tion of MGMT and the Notch1 pathways, treatments of
Shh, or a combination of Shh and TMZ were performed,
and the results showed increased MGMT, Notch1, and
Hes1 expression following Shh exposure. Moreover, Shh
augmented the TMZ-induced effect when combined
with Shh and TMZ, compared to TMZ alone. (*P < 0.05,
***P < 0.001). This indicated a regulatory role of
GANT61 in the regulation of expression of MGMT and
the Notch1 pathway. However, further study is needed
to confirm this.
Discussion
GBM, characterized by a high proliferative and invasive
capability, is refractory to traditional surgical tumor resec-
tion supplemented with chemotherapy or radiotherapy.
Thus, the outcome of GBM patients remains poor [32].
Alkylating agents, including TMZ and carmustine, readily
cross the blood–brain barrier and show cytotoxicity
against GBM [11]. TMZ induces DNA lesion O6-methyl-
guanine, and this would activate the repair pathways in
feedback, accounting for TMZ-resistance [33]. Emerging
literatures have revealed that Hh signaling affects almost
all DNA repair types by enabling tumor cells to survive
DNA damage induced by chemotherapy [18]. In addition,
activating mutations in the Hh pathway causes a large per-
centage of tumors [34]. GLIs are the effector molecules of
the Hh pathway and therefore we investigated the role of
GLI-specific inhibitor GANT61 in glioma survival. In our
study, GANT61 alone could dampen the proliferation of
glioma cells. Moreover, GANT61 potentiates TMZ cyto-
toxicity due to inhibiting DNA damage-repair initiated by
Fig. 4 GANT61 increased TMZ-induced invasion in glioma cells. Cell invasion was analyzed using the Transwell assay. Transwell assay showed the
invasive capability of (a) U251 and (b) U87 cells treated with GANT61, TMZ and the combination therapy. GANT61 or TMZ reduced the invasion
of glioma cells and their combination showed much lower invasion as demonstrated by representative microscope graphs (10 × 30). *P < 0.05,
**P < 0.01 compared with control group. The results were presented as the mean of three independent experiments
Li et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:184 Page 7 of 14
Fig. 5 (See legend on next page.)
Li et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:184 Page 8 of 14
(See figure on previous page.)
Fig. 5 GANT61 increased apoptosis of glioma cells treated with TMZ. Apoptosis of cells under different treatments were detected by flow cytometric
analysis with Annexin V-FITC/PI staining. a U251 and (b) U87. Left: The representative quadrantal diagrams showing results of flow cytometric analysis.
Right: Histogram manifested average apoptosis rates in cell groups of different treatments. GANT61 and TMZ treatment resulted in only a slight increase
in apoptosis. *P< 0.05. Combined GANT61 and TMZ treatment resulted in a significant increase in early apoptosis rate compared to cells treated with
GANT61 or TMZ alone, *P< 0.05, **P< 0.01. All data were representative of three independent experiments
Fig. 6 Combining GANT61 and TMZ treatment reversed EMT of glioma cells. a The mRNA expression levels of different genes. qRT-PCR analysis
demonstrated that either GANT61 or TMZ treatment resulted in a reduction of N-cadherin, Vimentin and Fibronectin mRNA expression and an
elevation of E-cadherin mRNA expression. The combination of GANT61 and TMZ treatment led to more significant decreases in N-cadherin,
Vimentin and Fibronectin mRNA expression and increase in E-cadherin mRNA expression than cells treated with GANT61 or TMZ treatment alone.
*P < 0.05, **P < 0.01, ***P < 0.001. b Western blot analysis showed that the protein expression of N-cadherin, Vimentin and Fibronectin decreased,
and the protein expression of E-cadherin increased in cells, especially in the GANT61 + TMZ group, while only a slight change was detected in
the TMZ group. This experiment was repeated three times
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Fig. 7 (See legend on next page.)
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Fig. 7 GANT61 enhanced the DNA damage effect initiated by TMZ treatment. a Western blot analysis showed an obviously decreased expression of
Gli1 and Gli2 in cells treated with a combination of GANT61 and TMZ, compared to TMZ-treated U251 and U87 glioma cells. Cells were continuously
exposed to 5 μM GANT61 or 100 μM TMZ for up to 48 h. GAPDH was used as the loading control. b U87 and U251 cells were treated with 5 μM
GANT61, 100 μM TMZ or a combination of the two treatments for 48 h. The γH2AX levels were measured by immunoblot assay. c Representative
comet staining images in U87 and U251 cells after different treatments (5 μM GANT61, 100 μM TMZ or both). d Quantitative assessment of comet tail
moment. **P < 0.01
Fig. 8 GANT61 abrogated the MGMT, Notch1, and Hes1 overexpression induced by TMZ treatment. a qRT-PCR analysis of MGMT, Notch1, and Hes1
mRNA expression after incubation with GANT61, TMZ, GANT61 + TMZ, Shh, and Shh + TMZ for 48 h. Under TMZ, Shh or Shh + TMZ treatment, MGMT,
Notch1, and Hes1 mRNA levels were much higher than the indicated treatment (TMZ vs. Control; Shh vs. Control; Shh + TMZ vs. TMZ). GANT61-treated
cells showed decreased MGMT, Notch1, and Hes1 mRNA expression, especially in GANT61 + TMZ (GANT61 vs. Control; GANT61 + TMZ vs. TMZ).
*P < 0.05, **P < 0.01, ***P < 0.001. b Western blot analysis revealed increased MGMT, Notch1, and Hes1 protein expression in U87 and U251 glioma cells
treated with TMZ. However, the GANT61 + TMZ group had lower levels of MGMT, Notch1, and Hes1 protein than the TMZ group when the same dose
of TMZ was used, while GANT61 showed a lower expression than the control group and Shh + TMZ group had higher expression than the TMZ group.
The results shown were representative of three independent experiments
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TMZ treatment. Treatment with the same doses (2.5 to
10 μM) for the same period (24/48 h) does not cause sig-
nificant damage to OL cells, which suggests appropriate
doses for studying in vivo or clinical investigation. This is
conducive to the development of precision treatment.
Simultaneously, elevated expression of the repair protein
MGMT also results in TMZ resistance [33]. MGMT can
eliminate the cytotoxic O6-methylguanine DNA adduct
[11]. In our study, we found that TMZ treatment in-
creased the expression of MGMT, but is abolished by
GANT61. This suggests that blocking the Hh pathway en-
hances the cytotoxicity of TMZ in glioma cells by down-
regulating the expression of MGMT. As described above,
GANT61 sensitized glioma cells to TMZ via enhancing
apoptosis and inhibiting proliferation/invasion. However,
the downstream factors mediating these effects remain to
be investigated. The expression of a series of tumor sup-
pressors and oncogenes relating to cancer cell apoptosis,
invasion and TMZ resistance were compared among gli-
oma cells treated with TMZ or GANT61 or a combination
of the two. We found that Notch1 and Hes1 were signifi-
cantly upregulated in TMZ-treated glioma cells, but not
in the combination of TMZ and GANT61-treated glioma
cells. Notch1 and Hes1 have been demonstrated to be
important oncogenes playing critical roles in glioma cell
survival and TMZ resistance [35]. Furthermore, the Notch
pathway interacts closely with the Hh pathway. For in-
stance, Notch directly suppresses Hh via Hes1-mediated
inhibition of Gli1 transcription [36]. Ectopic Notch activa-
tion increases Gli2 protein [37]. Hh signaling promotes
proliferation of monociliated choroid plexus tumor cells
in a Notch-dependent pathway [21]. Inactivating Hh re-
sults in decreased expression of the Hh/Notch signaling
component [20]. Inhibiting the Hh pathway suppresses
Notch signaling and induces a mesenchymal-to-epithelial-
like transition [19]. Both the Hh and Notch pathways par-
ticipate in tumorigenesis and TMZ resistance. Thus, it is
logical to suppose that glioma cells resistant to TMZ and
protect themselves partly through the activity of Notch1
pathway, while GANT61 somehow abrogated this upregu-
lation, reducing the chemoresistance and at last sensitizing
glioma cells to TMZ. The activation of the Notch pathway
after TMZ therapy was suspected to confer DNA damage
repair. However, further study is required to confirm this.
EMT is a process whereby cells acquire morphologic and
molecular alterations that facilitate tumor metastasis and
progression. Emerging evidence associates chemoresistance
with the acquisition of EMT in cancer [38, 39]. The in-
duced EMT was associated with increased cell motility, in-
vasiveness, and clonogenicity. Hh signaling promotes EMT,
and antagonizing Hh signaling inhibits EMT in a GLI-
dependent manner [40–44]. Herein, we investigate the
combination effect of GLI inhibitor and TMZ on EMT. To
the best of our knowledge, this is the first report that
treatment with a combination of TMZ and GANT61 can
reverse the EMT of glioma cells.
Conclusion
To conclude, downregulation of the Hh pathway by
GANT61 enhances the cytotoxicity of TMZ via inhibiting
proliferation, suppressing invasion/EMT, and inducing
apoptosis. The synergistic mechanism is suggested that
down-regulation of the Hh pathway by GANT61, which
enhances DNA damage effect and suppresses MGMT and
the Notch1 pathway, induces sensitivity to TMZ. These
results indicated that GANT61 may represent a potential
targeted inhibitor for glioma treatment and may increase
the chemo-sensitivity of glioma to TMZ.
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